Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806866 | 0.95 | HTR1A (0.41) | CCR2HTR1ASIGMAR1ACHEGAA | |
| SCHEMBL13018984 | 0.94 | CCR2 (0.43) | CCR2GAASMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3789044 | 0.89 | CCR2 (0.43) | CCR2GAASMN1; SMN2CYP2D6TSHR | |
| SCHEMBL13806697 | 0.87 | CCR2 (0.39) | CCR2HTR1AGAASMN1; SMN2CYP2D6 | |
| SCHEMBL3788335 | 0.85 | CCR2 (0.44) | CCR2GAASMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3779151 | 0.84 | CCR2 (0.44) | CCR2GAASMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3784130 | 0.82 | CCR2 (0.43) | CCR2GAASMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3786892 | 0.81 | CCR2 (0.36) | CCR2HTR1ASIGMAR1GAASMN1; SMN2 | |
| SCHEMBL3038231 | 0.79 | GAA (0.49) | CCR2ACHEGAASMN1; SMN2CYP2D6 | |
| SCHEMBL3034250 | 0.79 | FAAH (0.44) | CCR2GAASMN1; SMN2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | claimed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | CCR2 1/4885HTR1A 558/4885SIGMAR1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.